Maxence Mancini

Maxence Mancini

Auto-generated profile, based on publicly available information

Maxence Mancini

Department of Pharmacology and Tumor Genomics, DMU BioGeM, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Histopathology
Verified
Journal Article
Open access
MLMélanie Legrand
Mélanie Legrand
BLBaptiste Louveau
Baptiste Louveau
NMNicolas Macagno
Nicolas Macagno
MMMaxence Mancini
Maxence Mancini
DKDmitry V Kazakov
Dmitry V Kazakov
TKThibault Kervarrec
Thibault Kervarrec
Aims: Sebaceous neoplasms constitute a group of adnexal tumours, including sebaceous adenoma, sebaceoma and sebaceous carcinoma. Although mismatch repair deficiency may be observed, the nature of the genetic alterations contributing to the development of most of these tumours is still unknown. In the present study, we describe the clinical, microscopic, and molecular features of eight sebaceomas with GRHL gene rearrangement.Methods and results: Among these sebaceomas, four occurred in women and four in men; the median age was 63 years (range = 29–89). The tumours were located in the head and neck area in all cases. Microscopic examination revealed a well‐demarcated lesion located in the dermis with focal extension into the subcutaneous tissue (three cases). The neoplasms displayed macronodular (eight cases), cribriform (seven cases) and organoid (six cases) growth patterns, occurring in combination. The tumours were mainly composed of immature basophilic cells associated with scattered mature sebocytes. Numerous small infundibular cysts were present in seven cases. Mitotic activity was low (none/one to four mitoses/mm2). Immunohistochemistry showed positivity for androgen receptor and p63. Preserved expression of MLH1, PMS2, MSH2 and MSH6 was observed in all cases. RNA‐sequencing revealed RCOR1::GRHL2 (three cases), BCL6::GRHL1 (two cases), a BCOR::GRHL2 (one case), RCOR1::GRHL1 (one case) and TLE1::GRHL1 (one case) fusion transcript. Methylation analysis demonstrated that GRHL‐fused sebaceomas form an independent cluster and highlight the proximity of such tumours with poromas with folliculo‐sebaceous differentiation.Conclusions: In conclusion, we report recurrent fusions of the GRHL genes in a distinctive subset of sebaceomas harbouring infundibulocystic differentiation, a frequent organoid growth pattern and lack of mismatch repair deficiency.

18 April 2025 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
MTMinh Chau Ta
Minh Chau Ta
CGCamille Gandon
Camille Gandon
MMMaxence Mancini
Maxence Mancini
PLPhilippe Lantier
Philippe Lantier
OMOlaf Mercier
Olaf Mercier
Maxime BattistellaMaxime Battistella
Maxime Battistella

13 December 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
BLBaptiste Louveau
Baptiste Louveau
FJFanélie Jouenne
Fanélie Jouenne
CRCaroline Ram-Wolff
Caroline Ram-Wolff
MMMaxence Mancini
Maxence Mancini
AMAdèle De Masson
Adèle De Masson
Maxime BattistellaMaxime Battistella
Maxime Battistella
Identifying pathognomonic features that differentiate primary cutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) from other CD8+ aggressive lymphomas is a major concern. Doing so can facilitate diagnosis and allow clinicians to optimize clinical management. In this context, we read with great interest the article from Wobser et al., which proposed a molecular characterization of five cutaneous acral CD8+ TLPDs and identified KIR3DL1 alterations in addition to PIK3R1 alterations. To broaden this spectrum, we propose genomic profiling of six cutaneous acral CD8+ TLPDs from our database and identify alterations related to oncogenic pathways such as the AKT pathway and the Janus kinase–signal transducer and activator of transcription protein pathway. We also confirm the decreased mRNA expression of KIR3DL1 in this setting.

28 August 2025 in Annales de Dermatologie et de Vénéréologie
Verified
Journal Article
Closed access
LGL. Garcia
L. Garcia
SWS. Wylomanski
S. Wylomanski
AAA. Alirkilicarslan
A. Alirkilicarslan
Maxime BattistellaMaxime Battistella
Maxime Battistella
MMM. Mancini
M. Mancini
LHL. Hefez
L. Hefez